Found: 2
Select item for more details and to access through your institution.
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
- Published in:
- Pharmacology Research & Perspectives, 2018, v. 6, n. 1, p. 1, doi. 10.1002/prp2.380
- By:
- Publication type:
- Article
Biosimilars in rheumatology: understanding the rigor of their development.
- Published in:
- Rheumatology, 2017, v. 56, n. 2, p. 187, doi. 10.1093/rheumatology/kew206
- By:
- Publication type:
- Article